{"id":"https://openalex.org/W4297989154","doi":"https://doi.org/10.1007/s40273-022-01189-9","title":"A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia","display_name":"A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia","publication_year":2022,"publication_date":"2022-09-30","ids":{"openalex":"https://openalex.org/W4297989154","doi":"https://doi.org/10.1007/s40273-022-01189-9","pmid":"https://pubmed.ncbi.nlm.nih.gov/36175789"},"language":"en","primary_location":{"id":"doi:10.1007/s40273-022-01189-9","doi":"https://doi.org/10.1007/s40273-022-01189-9","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s40273-022-01189-9","pdf_url":null,"source":{"id":"https://openalex.org/S43019230","display_name":"PharmacoEconomics","issn_l":"1170-7690","issn":["1170-7690","1179-2027"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103791887","display_name":"Rumjhum Agrawal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210090302","display_name":"Novartis (India)","ror":"https://ror.org/00dhvr506","country_code":"IN","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210090302"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Rumjhum Agrawal","raw_affiliation_strings":["Novartis Healthcare Pvt. Ltd., Hyderabad, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Healthcare Pvt. Ltd., Hyderabad, India","institution_ids":["https://openalex.org/I4210090302"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066747535","display_name":"Jo\u00e3o Vieira","orcid":"https://orcid.org/0000-0001-6309-329X","observed_orcids":["https://orcid.org/0000-0001-6309-329X"]},"institutions":[{"id":"https://openalex.org/I4210129647","display_name":"Novartis (United Kingdom)","ror":"https://ror.org/039s6n838","country_code":"GB","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210129647"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Joao Vieira","raw_affiliation_strings":["Novartis Pharmaceuticals UK Ltd., London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals UK Ltd., London, UK","institution_ids":["https://openalex.org/I4210129647"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090863193","display_name":"Jacqueline Ryan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210129647","display_name":"Novartis (United Kingdom)","ror":"https://ror.org/039s6n838","country_code":"GB","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210129647"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jacqueline Ryan","raw_affiliation_strings":["Novartis Pharmaceuticals UK Ltd., London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals UK Ltd., London, UK","institution_ids":["https://openalex.org/I4210129647"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062483820","display_name":"Harish Negi","orcid":"https://orcid.org/0000-0001-9264-7562","observed_orcids":["https://orcid.org/0000-0001-9264-7562"]},"institutions":[{"id":"https://openalex.org/I4210090302","display_name":"Novartis (India)","ror":"https://ror.org/00dhvr506","country_code":"IN","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210090302"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Harish Negi","raw_affiliation_strings":["Novartis Healthcare Pvt. Ltd., Hyderabad, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Healthcare Pvt. Ltd., Hyderabad, India","institution_ids":["https://openalex.org/I4210090302"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007269025","display_name":"Tanvi Rajput","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210090302","display_name":"Novartis (India)","ror":"https://ror.org/00dhvr506","country_code":"IN","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210090302"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Tanvi Rajput","raw_affiliation_strings":["Novartis Healthcare Pvt. Ltd., Hyderabad, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Healthcare Pvt. Ltd., Hyderabad, India","institution_ids":["https://openalex.org/I4210090302"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060268357","display_name":"Regina Corbin","orcid":"https://orcid.org/0000-0002-3664-0187","observed_orcids":["https://orcid.org/0000-0002-3664-0187"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Regina Corbin","raw_affiliation_strings":["Novartis Pharmaceuticals Corp., East Hanover, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corp., East Hanover, NJ, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101761629","display_name":"Ricardo Viana","orcid":"https://orcid.org/0000-0001-9261-6942","observed_orcids":["https://orcid.org/0000-0001-9261-6942"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":true,"raw_author_name":"Ricardo Viana","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland. ricardo.viana@novartis.com","Worldwide Access Disease Lead, Hematology, Global Value & Access, Oncology, WSJ- Fabrikstrasse 18-3.330, 4056, Basel, Switzerland. ricardo.viana@novartis.com","Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland. ricardo.viana@novartis.com","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Worldwide Access Disease Lead, Hematology, Global Value & Access, Oncology, WSJ- Fabrikstrasse 18-3.330, 4056, Basel, Switzerland. ricardo.viana@novartis.com","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5101761629"],"corresponding_institution_ids":["https://openalex.org/I1283582996"],"apc_list":{"value":4290,"currency":"USD","value_usd":4290},"apc_paid":null,"fwci":0.1175,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.27462341,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"40","issue":"12","first_page":"1159","last_page":"1186"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9365000128746033,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9365000128746033,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.05469999834895134,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":1.0},{"id":"https://openalex.org/keywords/chronic-phase","display_name":"chronic phase","score":0.6940000057220459},{"id":"https://openalex.org/keywords/economic-evaluation","display_name":"economic evaluation","score":0.7419999837875366},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8920000195503235},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9390000104904175},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.9959999918937683},{"id":"https://openalex.org/keywords/nilotinib","display_name":"nilotinib","score":0.996999979019165},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/bosutinib","display_name":"bosutinib","score":0.9660000205039978},{"id":"https://openalex.org/keywords/ponatinib","display_name":"ponatinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/interferon-alpha","display_name":"interferon-alpha","score":0.7360000014305115},{"id":"https://openalex.org/keywords/hydroxyurea","display_name":"hydroxyurea","score":0.9810000061988831},{"id":"https://openalex.org/keywords/allogeneic-stem-cell-transplantation","display_name":"allogeneic stem cell transplantation","score":0.9679999947547913},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.6970000267028809},{"id":"https://openalex.org/keywords/health-technology-assessment","display_name":"health technology assessment","score":0.6240000128746033},{"id":"https://openalex.org/keywords/cost-utility-analysis","display_name":"cost-utility analysis","score":0.6290000081062317},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.6309999823570251},{"id":"https://openalex.org/keywords/third-line-therapy","display_name":"third-line therapy","score":0.8870000243186951}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8417325615882874},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.7916754484176636},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.7182139158248901},{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.6237699389457703},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.602267861366272},{"id":"https://openalex.org/C2776960273","wikidata":"https://www.wikidata.org/wiki/Q729735","display_name":"Chronic myelogenous leukemia","level":3,"score":0.5303158164024353},{"id":"https://openalex.org/C2778208673","wikidata":"https://www.wikidata.org/wiki/Q894611","display_name":"Bosutinib","level":5,"score":0.48239457607269287},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3730356693267822},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3285856246948242},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3220256567001343},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3184013366699219}],"mesh":[{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000069439","descriptor_name":"Dasatinib","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013222","descriptor_name":"State Medicine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019057","descriptor_name":"Quality-Adjusted Life Years","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1007/s40273-022-01189-9","doi":"https://doi.org/10.1007/s40273-022-01189-9","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s40273-022-01189-9","pdf_url":null,"source":{"id":"https://openalex.org/S43019230","display_name":"PharmacoEconomics","issn_l":"1170-7690","issn":["1170-7690","1179-2027"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics","raw_type":"journal-article"},{"id":"pmid:36175789","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36175789","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics","raw_type":"Systematic Review"},{"id":"pmh:oai:RePEc:spr:pharme:v:40:y:2022:i:12:d:10.1007_s40273-022-01189-9","doi":null,"is_oa":false,"landing_page_url":"http://link.springer.com/10.1007/s40273-022-01189-9","pdf_url":null,"source":{"id":"https://openalex.org/S4306401271","display_name":"RePEc: Research Papers in Economics","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I77793887","host_organization_name":"Federal Reserve Bank of St. Louis","host_organization_lineage":["https://openalex.org/I77793887"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":62,"referenced_works":["https://openalex.org/W61037842","https://openalex.org/W1593173821","https://openalex.org/W1621922121","https://openalex.org/W1951618115","https://openalex.org/W1960354891","https://openalex.org/W1976432754","https://openalex.org/W1998742987","https://openalex.org/W2011310650","https://openalex.org/W2017737463","https://openalex.org/W2021452576","https://openalex.org/W2022316777","https://openalex.org/W2032274468","https://openalex.org/W2050789361","https://openalex.org/W2055198551","https://openalex.org/W2070324087","https://openalex.org/W2085255253","https://openalex.org/W2091403456","https://openalex.org/W2098820223","https://openalex.org/W2110757912","https://openalex.org/W2145529820","https://openalex.org/W2162269315","https://openalex.org/W2178307115","https://openalex.org/W2181125686","https://openalex.org/W2236676365","https://openalex.org/W2266168940","https://openalex.org/W2291265461","https://openalex.org/W2294564449","https://openalex.org/W2396911106","https://openalex.org/W2549518260","https://openalex.org/W2554824737","https://openalex.org/W2557460214","https://openalex.org/W2567515699","https://openalex.org/W2737446049","https://openalex.org/W2763919110","https://openalex.org/W2810929131","https://openalex.org/W2890077744","https://openalex.org/W2899856380","https://openalex.org/W2907985740","https://openalex.org/W2920458604","https://openalex.org/W2944320945","https://openalex.org/W2952650636","https://openalex.org/W2953483893","https://openalex.org/W2953589658","https://openalex.org/W2983817583","https://openalex.org/W2986151716","https://openalex.org/W2987924812","https://openalex.org/W2995921845","https://openalex.org/W2996057723","https://openalex.org/W3009751715","https://openalex.org/W3028494787","https://openalex.org/W3048361238","https://openalex.org/W3092607363","https://openalex.org/W3118615836","https://openalex.org/W3137918025","https://openalex.org/W3153733153","https://openalex.org/W3179731829","https://openalex.org/W3185045240","https://openalex.org/W3189242320","https://openalex.org/W3197464566","https://openalex.org/W3213158727","https://openalex.org/W4292399048","https://openalex.org/W4294307875"],"related_works":["https://openalex.org/W2890077744","https://openalex.org/W3171724792","https://openalex.org/W2552043281","https://openalex.org/W2343040013","https://openalex.org/W4394345302","https://openalex.org/W76828481","https://openalex.org/W3153733153","https://openalex.org/W2763919110","https://openalex.org/W2044484102","https://openalex.org/W1946729496"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2022-10-01T00:00:00"}